TrianglePUBLICATIONS · 34921960
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Ann Oncol
- Publication date
- 2022 Mar
- First author
- Horwitz S
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Horwitz S
- type
- Author
- name
- O'Connor OA
- type
- Author
- name
- Pro B
- type
- Author
- name
- Trümper L
- type
- Author
- name
- Iyer S
- type
- Author
- name
- Advani R
- type
- Author
- name
- Bartlett NL
- type
- Author
- name
- Christensen JH
- type
- Author
- name
- Morschhauser F
- type
- Author
- name
- Domingo-Domenech E
- type
- Author
- name
- Rossi G
- type
- Author
- name
- Kim WS
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Horwitz S
- type
- Author
- name
- O'Connor OA
- type
- Author
- name
- Pro B
- type
- Author
- name
- Trümper L
- type
- Author
- name
- Iyer S
- type
- Author
- name
- Advani R
- type
- Author
- name
- Bartlett NL
- type
- Author
- name
- Christensen JH
- type
- Author
- name
- Morschhauser F
- type
- Author
- name
- Domingo-Domenech E
- type
- Author
- name
- Rossi G
- type
- Author
- name
- Kim WS
- type
- Author
- bibliography ids
- nci-bib-d7ae36d6a821381d3f4e2ba0
- book metadata
- content sha256
- ead37bb5b662aff6e7354aa1bc8781f091d0be387f931479137cec473c11e8f3
- document type
- citation
- dois
- 10.1016/j.annonc.2021.12.002
- electronic publication date
- display
- 2021 Dec 16
- precision
- day
- year
- 2021
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:34921960
- immutable id
- pubmed:34921960@ead37bb5b662aff6e7354aa1bc8781f091d0be387f931479137cec473c11e8f3
- journal
- abbreviation
- Ann Oncol
- issn electronic
- 1569-8041
- issn print
- 0923-7534
- issue
- 3
- name
- Annals of oncology : official journal of the European Society for Medical Oncology
- nlm unique id
- 9007735
- pages
- 288-298
- volume
- 33
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 34921960
- provenance
- batch id
- 3f4d1914d2afe41e9e70
- provider
- NCBI PubMed ESummary
- record sha256
- ebb88c7dc5e233e4ef2e04807ef120535ba2a4cc97402fe35c8f9c7c1f974011
- response sha256
- 0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
- retrieved at
- 2026-09-09T23:48:06.522634+00:00
- publication date
- display
- 2022 Mar
- precision
- month
- year
- 2022
- publication types
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
Preserved source evidence · Independent clinical review pending · Not medical advice